Cancer-Associated Hypercalcemia

被引:56
作者
Guise, Theresa A. [1 ,2 ,3 ]
Wysolmerski, John J. [4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Sect Bone & Mineral Disorders, Houston, TX 77030 USA
[2] Lawrence Bone Dis Program Texas, Houston, TX 77030 USA
[3] Canc Prevent Res Inst Texas, Austin, TX 78701 USA
[4] Yale Sch Med, Dept Med, Sect Endocrinol & Metab, New Haven, CT USA
关键词
HORMONE-RELATED PROTEIN; MALIGNANCY-ASSOCIATED HYPERCALCEMIA; ZOLEDRONIC ACID; HUMORAL HYPERCALCEMIA; DOUBLE-BLIND; DENOSUMAB; PAMIDRONATE; METASTASES; PREVENTION; EXPERIENCE;
D O I
10.1056/NEJMcp2113128
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 60-year-old woman presents to the emergency department with somnolence and poor appetite. Five months earlier, she received a diagnosis of invasive, high-grade, urothelial carcinoma and underwent four cycles of neoadjuvant chemotherapy, and 1 month earlier, she underwent open radical cystectomy. She has no other significant medical history. The serum calcium level is 16.1 mg per deciliter (4.02 mmol per liter; reference range, 8.8 to 10.2 mg per deciliter [2.2 to 2.5 mmol per liter]); previous serum calcium levels were normal. The albumin level is 4 g per deciliter, blood urea nitrogen 27 mg per deciliter (9.6 mmol per liter), creatinine 1.2 mg per deciliter (106.1 mu mol per liter), and phosphorus 2.1 mg per deciliter (0.7 mmol per liter). The parathyroid hormone (PTH) level is 10 pg per milliliter (reference range, 15 to 65), parathyroid hormone-related protein (PTHrP) 187 pg per milliliter (reference range, 14 to 27), 25-hydroxyvitamin D 28 ng per milliliter (70 nmol per liter; reference range, 20 to 50 ng per milliliter [50 to 125 nmol per liter]), and 1,25-dihydroxyvitamin D 77 pg per milliliter (200 nmol per liter; reference range, 25 to 66 pg per milliliter [65 to 172 nmol per liter]). A whole-body bone scan shows no skeletal metastases. How should this patient be treated?
引用
收藏
页码:1443 / 1451
页数:9
相关论文
共 55 条
[21]   Prevalence of hypercalcemia among cancer patients in the United States [J].
Gastanaga, Victor M. ;
Schwartzberg, Lee S. ;
Jain, Rajul K. ;
Pirolli, Melissa ;
Quach, David ;
Quigley, Jane M. ;
Mu, George ;
Stryker, W. Scott ;
Liede, Alexander .
CANCER MEDICINE, 2016, 5 (08) :2091-2100
[22]   Parathyroid hormone related protein (PTHrP) and hypercalcaemia [J].
Grill, V ;
Rankin, W ;
Martin, TJ .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (02) :222-229
[23]   Hypercalcemia of Malignancy [J].
Grill V. ;
Martin T.J. .
Reviews in Endocrine and Metabolic Disorders, 2000, 1 (4) :253-263
[24]   PARATHYROID HORMONE-RELATED PROTEIN AND RESPONSE TO PAMIDRONATE IN TUMOR-INDUCED HYPERCALCEMIA [J].
GURNEY, H ;
GRILL, V ;
MARTIN, TJ .
LANCET, 1993, 341 (8861) :1611-1613
[25]   Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma [J].
Henry, David H. ;
Costa, Luis ;
Goldwasser, Francois ;
Hirsh, Vera ;
Hungria, Vania ;
Prausova, Jana ;
Scagliotti, Giorgio Vittorio ;
Sleeboom, Harm ;
Spencer, Andrew ;
Vadhan-Raj, Saroj ;
von Moos, Roger ;
Willenbacher, Wolfgang ;
Woll, Penella J. ;
Wang, Jianming ;
Jiang, Qi ;
Jun, Susie ;
Dansey, Roger ;
Yeh, Howard .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) :1125-1132
[26]   Hypercalcemia following discontinuation of denosumab therapy: A systematic review [J].
Horiuchi, Keisuke ;
Kobayashi, Eisuke ;
Mizuno, Tsukasa ;
Susa, Michiro ;
Chiba, Kazuhiro .
BONE REPORTS, 2021, 15
[27]   Denosumab for Treatment of Hypercalcemia of Malignancy [J].
Hu, Mimi I. ;
Glezerman, Ilya G. ;
Leboulleux, Sophie ;
Insogna, Karl ;
Gucalp, Rasim ;
Misiorowski, Waldemar ;
Yu, Bennett ;
Zorsky, Paul ;
Tosi, Diego ;
Bessudo, Alberto ;
Jaccard, Arnaud ;
Tonini, Giuseppe ;
Ying, Wendy ;
Braun, Ada ;
Jain, Rajul K. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (09) :3144-3152
[28]   SURVIVAL IN HYPERCALCEMIC PATIENTS WITH CANCER AND COEXISTING PRIMARY HYPERPARATHYROIDISM [J].
HUTCHESSON, ACJ ;
BUNDRED, NJ ;
RATCLIFFE, WA .
POSTGRADUATE MEDICAL JOURNAL, 1995, 71 (831) :28-31
[29]  
Jin Joon, 2017, J Bone Metab, V24, P249, DOI 10.11005/jbm.2017.24.4.249
[30]   PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer [J].
Kir, Serkan ;
Komaba, Hirotaka ;
Garcia, Ana P. ;
Economopoulos, Konstantinos P. ;
Liu, Wei ;
Lanske, Beate ;
Hodin, Richard A. ;
Spiegelman, Bruce M. .
CELL METABOLISM, 2016, 23 (02) :315-323